

血液

第1章 輸液総論

● 参考文献

1. 日本赤十字社. 製品情報.<<http://www.jrc.or.jp/mr/product/>>
2. 厚生労働省. 「輸血療法の実施に関する指針」及び「血液製剤の使用指針」の一部改正について.<<http://www.mhlw.go.jp/stf/seisakunitsuite/bunya/0000065580.html>>
3. Shah A, et al. Evidence and triggers for the transfusion of blood and blood products. *Anaesthesia* 2015; 70 Suppl 1: 10-9, e3-5. PMID: 25440390
4. Carson JL, et al. Clinical practice guidelines from the AABB: Red blood cell transfusion thresholds and storage. *JAMA* 2016; 316: 2025-35. PMID: 27732721
5. Hébert PC, et al. A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. Transfusion Requirements in Critical Care Investigators, Canadian Critical Care Trials Group. *N Engl J Med* 1999; 340: 409-17. PMID: 9971864
6. Carson JL, et al. Transfusion thresholds and other strategies for guiding allogeneic red blood cell transfusion. *Cochrane Database Syst Rev* 2012; (4): CD002042. PMID: 22513904
7. Cooper HA, et al. Conservative versus liberal red cell transfusion in acute myocardial infarction (the CRIT Randomized Pilot Study). *Am J Cardiol* 2011; 108: 1108-11. PMID: 21791325
8. Carson JL, et al. Coronary artery disease: Liberal versus restrictive transfusion thresholds for patients with symptomatic coronary artery disease. *Am Heart J* 2013; 165: 964-971.e1. PMID: 23708168
9. Roback JD, et al. Evidence-based practice guidelines for plasma transfusion. *Transfusion* 2010; 50: 1227-39. PMID: 20345562
10. 日本赤十字社. 輸血情報. 新鮮凍結血漿 (FFP) の融解方法について.<http://www.jrc.or.jp/vcms_lf/iyakuhin_yuketuj0902-117_090805.pdf>
11. Kaufman RM, et al. Platelet transfusion: a clinical practice guideline from the AABB. *Ann Intern Med* 2015; 162: 205-13. PMID: 25383671
12. Goel R, et al. Platelet transfusions in platelet consumptive disorders are associated with arterial thrombosis and in-hospital mortality. *Blood* 2015; 125: 1470-6. PMID: 25588677
13. Winters JL. Plasma exchange: concepts, mechanisms, and an overview of the American Society for Apheresis guidelines. *Hematology Am Soc Hematol Educ Program* 2012; 2012: 7-12. PMID: 23233554
14. Finfer S, et al. A comparison of albumin and saline for fluid resuscitation in the intensive care unit. *N Engl J Med* 2004; 350: 2247-56. PMID: 15163774
15. SAFE Study Investigators, et al. Saline or albumin for fluid resuscitation in patients with traumatic brain injury. *N Engl J Med* 2007; 357: 874-84. PMID: 17761591
16. Caironi P, et al. Albumin replacement in patients with severe sepsis or septic shock. *N Engl J Med* 2014; 370: 1412-21. PMID: 24635772

17. Runyon BA, et al. Introduction to the revised American Association for the Study of Liver Diseases Practice Guideline management of adult patients with ascites due to cirrhosis 2012. *Hepatology* 2013; 57: 1651-3. PMID: 23463403
18. 日本血液製剤協会. 免疫グロブリン製剤の分類.<http://www.ketsukyo.or.jp/plasma/globulin/glo_05.html>
19. 厚生労働省. 免疫グロブリン製剤の効能・効果一覧.<<http://www.mhlw.go.jp/stf/shingi/2r9852000001dj72-att/2r9852000001djhc.pdf>>
20. Rhodes A, et al. Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016. *Crit Care Med* 2017; 45: 486-552. PMID: 28098591
21. 日本版敗血症診療ガイドライン 2016 作成特別委員会. 日本版敗血症診療ガイドライン 2016 (J-SS-CG2016). *日集中医誌* 2017; 24: S1-32.<<http://www.jsicm.org/pdf/jjsicm24Suppl2-2.pdf>>
22. Wikkelsø A, et al. Fibrinogen concentrate in bleeding patients. *Cochrane Database Syst Rev* 2013; (8): CD008864. PMID: 23986527
23. Sørensen B, et al. Clinical review: Prothrombin complex concentrates — evaluation of safety and thrombogenicity. *Crit Care* 2011; 15: 201. PMID: 21345266
24. CSL ベーリング株式会社. ケイセントラ® 静注用添付文書.<<https://www.cslproducts.com/di/binary/pdf/product/tenpu/kcentra.pdf>>
25. ノボノルディスクファーマ株式会社. ノボセプン® 静注用添付文書.<http://www.info.pmda.go.jp/downfiles/ph/PDF/620023_6343434D3020_1_07.pdf>
26. Yank V, et al. Systematic review: benefits and harms of in-hospital use of recombinant factor VIIa for off-label indications. *Ann Intern Med* 2011; 154: 529-40. PMID: 21502651
27. 日本輸血・細胞治療学会. 輸血副作用対応ガイド.<http://yuketsu.jstmct.or.jp/medical/side_effect/>
28. Kleinman S, et al. Toward an understanding of transfusion-related acute lung injury: statement of a consensus panel. *Transfusion* 2004; 44: 1774-89. PMID: 15584994
29. Vlaar AP, et al. Transfusion-related acute lung injury: a clinical review. *Lancet* 2013; 382: 984-94. PMID: 23642914
30. Pham HP, et al. Update on massive transfusion. *Br J Anaesth* 2013; 111 Suppl 1: i71-82. PMID: 24335401
31. Pohlman TH, et al. Damage control resuscitation. *Blood Rev* 2015; 29: 251-62. PMID: 25631636
32. Holcomb JB, et al. The prospective, observational, multicenter, major trauma transfusion (PROMTTT) study: comparative effectiveness of a time-varying treatment with competing risks. *Arch Surg*. 2012; 1. PMID: 23070371.
33. Holcomb JB, et al. Transfusion of plasma, platelets, and red blood cells in a 1:1:1 vs a 1:1:2 ratio and mortality in patients with severe trauma: the PROPPR randomized clinical trial. *JAMA* 2015; 313: 471-82. PMID: 25647203
34. Roberts I, et al. Effect of tranexamic acid on mortality in patients with traumatic bleeding: prespecified analysis of data from randomised controlled trial. *BMJ* 2012; 345: e5839. PMID: 22968527

● 関連 URL

- 2単位RBC-LRに含まれる上清総K量(日赤輸血情報): 照射赤血球濃厚液-LR「日赤」の安定性試験成績, 赤血球濃厚液-LR「日赤」の安定性試験成績
<<http://www.jrc.or.jp/mr/product/list/>>
- 赤十字血液センターに報告された非溶血性輸血副作用
<http://www.jrc.or.jp/mr/news/pdf/輸血情報_1707_155.pdf>
- エホバの証人 団体連絡先
<<https://www.jw.org/ja/medical-library/hospital-liaison-committee-hlc-contacts/>>
- 宗教的輸血拒否ガイドライン(日本輸血・細胞治療学会など5学会, 2008年)

<<http://yuketsu.jstmct.or.jp/wp-content/themes/jstmct/images/medical/file/guidelines/Ref13-1.pdf>>

第2章 血小板の生理および血小板減少に対するアプローチ

● 参考文献

1. Williamson DR, et al. Thrombocytopenia in critically ill patients receiving thromboprophylaxis : frequency, risk factors, and outcomes. *Chest* 2013 ; 144 : 1207-15. PMID : 23788287
2. van Bladel ER, et al. Functional platelet defects in children with severe chronic ITP as tested with 2 novel assays applicable for low platelet counts. *Blood* 2014 ; 123 : 1556-63. PMID : 24385537
3. Vanderschueren S, et al. Thrombocytopenia and prognosis in intensive care. *Crit Care Med* 2000 ; 28 : 1871-6. PMID : 10890635
4. Harker LA, et al. Thrombokinetics in man. *J Clin Invest* 1969 ; 48 : 963-74. PMID : 5814231
5. Zauli G, et al. In vitro senescence and apoptotic cell death of human megakaryocytes. *Blood* 1997 ; 90 : 2234-43. PMID : 9310474
6. Gurney AL, et al. Thrombocytopenia in c-mpl-deficient mice. *Science* 1994 ; 265 : 1445-7. PMID : 8073287
7. Choi ES, et al. The role of megakaryocyte growth and development factor in terminal stages of thrombopoiesis. *Br J Haematol* 1996 ; 95 : 227-33. PMID : 8904874
8. Schuster MW, et al. The effects of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) on platelet recovery in breast cancer patients undergoing autologous bone marrow transplantation. *Exp Hematol* 2002 ; 30 : 1044-50. PMID : 12225796
9. Rice TW, et al. Coagulopathy in critically ill patients : part 1 : platelet disorders. *Chest* 2009 ; 136 : 1622-30. PMID : 19995764
10. Nugent D, et al. Pathogenesis of chronic immune thrombocytopenia : increased platelet destruction and/or decreased platelet production. *Br J Haematol* 2009 ; 146 : 585-96. PMID : 19466980
11. Peck-Radosavljevic M, et al. Is inadequate thrombopoietin production a major cause of thrombocytopenia in cirrhosis of the liver? *J Hepatol* 1997 ; 27 : 127-31. PMID : 9252085
12. Mason KD, et al. Programmed anuclear cell death delimits platelet life span. *Cell* 2007 ; 128 : 1173-86. PMID : 17382885
13. Chong BH. Primary immune thrombocytopenia : understanding pathogenesis is the key to better treatments. *J Thromb Haemost* 2009 ; 7 : 319-21. PMID : 19077111
14. Leslie SD, et al. Laboratory hemostatic abnormalities in massively transfused patients given red blood cells and crystalloid. *Am J Clin Pathol* 1991 ; 96 : 770-3. PMID : 1746495
15. Aster RH. Pooling of platelets in the spleen : role in the pathogenesis of "hypersplenic" thrombocytopenia. *J Clin Invest* 1966 ; 45 : 645-57. PMID : 5327481
16. Nachman RL, et al. Platelets, petechiae, and preservation of the vascular wall. *N Engl J Med* 2008 ; 359 : 1261-70. PMID : 18799560
17. Ruggeri ZM, et al. Adhesion mechanisms in platelet function. *Circ Res* 2007 ; 100 : 1673-85. PMID : 17585075
18. Benigni A, et al. Reversible activation defect of the platelet glycoprotein II b-IIIa complex in patients with uremia. *Am J Kidney Dis* 1993 ; 22 : 668-76. PMID : 8238012
19. Cattaneo M. New P2Y12 inhibitors. *Circulation* 2010 ; 121 : 171-9. PMID : 20048234
20. Schömig A. Ticagrelor — is there need for a new player in the antiplatelet-therapy field? *N Engl J Med* 2009 ; 361 : 1108-11. PMID : 19717845
21. Goldenberg NA, et al. Brief communication : duration of platelet dysfunction after a 7-day course of Ibuprofen. *Ann Intern Med* 2005 ; 142 : 506-9. PMID : 15809462
22. Tholouli E, et al. Acquired Glanzmann's thrombasthenia without thrombocytopenia : a severe acquired

- autoimmune bleeding disorder. *Br J Haematol* 2004 ; 127 : 209-13. PMID : 15461628
23. De Luca G, et al. Abciximab as adjunctive therapy to reperfusion in acute ST-segment elevation myocardial infarction : a meta-analysis of randomized trials. *JAMA* 2005 ; 293 : 1759-65. PMID : 15827315
24. Berkman N, et al. EDTA-dependent pseudothrombocytopenia : a clinical study of 18 patients and a review of the literature. *Am J Hematol* 1991 ; 36 : 195-201. PMID : 1899964
25. Lan HH. Hemophilic arthropathy. *Radiol Clin North Am* 1996 ; 34 : 446-50. PMID : 8633126
26. Kuriyama K, et al. Diagnostic significance of detecting pseudo-Pelger-Huët anomalies and micro-megakaryocytes in myelodysplastic syndrome. *Br J Haematol* 1986 ; 63 : 665-9. PMID : 3460627
27. Kienast J, et al. Flow cytometric analysis of thiazole orange uptake by platelets : a diagnostic aid in the evaluation of thrombocytopenic disorders. *Blood* 1990 ; 75 : 116-21. PMID : 1688494
28. Rebullà P. Platelet transfusion trigger in difficult patients. *Transfus Clin Biol* 2001 ; 8 : 249-54. PMID : 11499971
29. Kaufman RM, et al. Platelet transfusion : a clinical practice guideline from the AABB. *Ann Intern Med* 2015 ; 162 : 205-13. PMID : 25383671
30. van Veen JJ, et al. The risk of spinal haematoma following neuraxial anaesthesia or lumbar puncture in thrombocytopenic individuals. *Br J Haematol* 2010 ; 148 : 15-25. PMID : 19775301
31. Zeidler K, et al. Optimal preprocedural platelet transfusion threshold for central venous catheter insertions in patients with thrombocytopenia. *Transfusion* 2011 ; 51 : 2269-76. PMID : 21517892
32. Avvisati G, et al. Thrombocytopenia and hemorrhagic risk in cancer patients. *Crit Rev Oncol Hematol* 2003 ; 48 (Suppl) : S13-6. PMID : 14563516
33. Goel R, et al. Platelet transfusions in platelet consumptive disorders are associated with arterial thrombosis and in-hospital mortality. *Blood* 2015 ; 125 : 1470-6. PMID : 25588677
34. François B, et al. Thrombocytopenia in the sepsis syndrome : role of hemophagocytosis and macrophage colony-stimulating factor. *Am J Med* 1997 ; 103 : 114-20. PMID : 9274894
35. George JN, et al. Syndromes of thrombotic microangiopathy. *N Engl J Med* 2014 ; 371 : 654-66. PMID : 25119611
36. Marchand A, et al. The predictive value of serum haptoglobin in hemolytic disease. *JAMA* 1980 ; 243 : 1909-11. PMID : 7365971
37. Burns ER, et al. Morphologic diagnosis of thrombotic thrombocytopenic purpura. *Am J Hematol* 2004 ; 75 : 18-21. PMID : 14695628
38. George JN. Clinical practice. Thrombotic thrombocytopenic purpura. *N Engl J Med* 2006 ; 354 : 1927-35. PMID : 16672704
39. George JN. How I treat patients with thrombotic thrombocytopenic purpura : 2010. *Blood* 2010 ; 116 : 4060-9. PMID : 20686117
40. Scully M, et al. Guidelines on the diagnosis and management of thrombotic thrombocytopenic purpura and other thrombotic microangiopathies. *Br J Haematol* 2012 ; 158 : 323-35. PMID : 22624596
41. George JN. How I treat patients with thrombotic thrombocytopenic purpura : 2010. *Blood* 2010 ; 116 : 4060-9. PMID : 20686117
42. Noris M, et al. Hemolytic uremic syndrome. *J Am Soc Nephrol* 2005 ; 16 : 1035-50. PMID : 15728781
43. Noris M, et al. Atypical hemolytic-uremic syndrome. *N Engl J Med* 2009 ; 361 : 1676-87. PMID : 19846853
44. Martel N, et al. Risk for heparin-induced thrombocytopenia with unfractionated and low-molecular-weight heparin thromboprophylaxis : a meta-analysis. *Blood* 2005 ; 106 : 2710-5. PMID : 15985543
45. Rauova L, et al. Role of platelet surface PF4 antigenic complexes in heparin-induced thrombocytopenia pathogenesis : diagnostic and therapeutic implications. *Blood* 2006 ; 107 : 2346-53. PMID : 16304054
46. Warkentin TE, et al. Non-necrotizing heparin-induced skin lesions and the 4T's score. *J Thromb Haem*

- most 2010 ; 8 : 1483-5. PMID : 20403090
47. Linkins LA, et al. Treatment and prevention of heparin-induced thrombocytopenia : Antithrombotic Therapy and Prevention of Thrombosis, 9th ed : American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012 ; 141 (2 Suppl) : e495S-530S.
48. Lo GK, et al. Evaluation of pretest clinical score (4 T's) for the diagnosis of heparin-induced thrombocytopenia in two clinical settings. J Thromb Haemost 2006 ; 4 : 759-65. PMID : 16634744
49. Warkentin TE, et al. Gender imbalance and risk factor interactions in heparin-induced thrombocytopenia. Blood 2006 ; 108 : 2937-41. PMID : 16857993
50. Prandoni P, et al. The incidence of heparin-induced thrombocytopenia in medical patients treated with low-molecular-weight heparin : a prospective cohort study. Blood 2005 ; 106 : 3049-54. PMID : 16030191
51. Lewis BE, et al. Effects of argatroban therapy, demographic variables, and platelet count on thrombotic risks in heparin-induced thrombocytopenia. Chest 2006 ; 129 : 1407-16. PMID : 16778256
52. Weigert AL, et al. Uremic bleeding : pathogenesis and therapy. Am J Med Sci 1998 ; 316 : 94-104. PMID : 9704663
53. Lindsay RM, et al. Improvement of platelet function by increased frequency of hemodialysis. Clin Nephrol 1978 ; 10 : 67-70. PMID : 699401
54. Gordz S, et al. Effect of desmopressin (DDAVP) on platelet membrane glycoprotein expression in patients with von Willebrand's disease. Clin Hemorheol Microcirc 2005 ; 32 : 83-7. PMID : 15764817
55. Zeigler ZR, et al. Desmopressin (d-DAVP) effects on platelet rheology and von Willebrand factor activities in uremia. Am J Hematol 1992 ; 39 : 90-5. PMID : 1550112

第3章 赤血球の生理および貧血の対応

● 参考文献

1. Asada N, et al. Dysfunction of fibroblasts of extrarenal origin underlies renal fibrosis and renal anemia in mice. J Clin Invest 2011 ; 121 : 3981-90. PMID : 21911936
2. Anemia and Red Blood Cell Transfusions. In : Marino PL. Marino's The ICU book. Philadelphia : Wolters Kluwer Health/Lippincott Williams & Wilkins, 2014 (稲田英一監訳. ICUブック. 第4版. 東京 : メディカル・サイエンス・インターナショナル, 2015).
3. Hébert PC, et al. Physiologic aspects of anemia. Crit Care Clin 2004 ; 20 : 187-212. PMID : 15135460
4. Hébert PC, et al. Clinical consequences of anemia and red cell transfusion in the critically ill. Crit Care Clin 2004 ; 20 : 225-35. PMID : 15135462
5. Weiskopf RB, et al. Human cardiovascular and metabolic response to acute, severe isovolemic anemia. JAMA 1998 ; 279 : 217-21. PMID : 9438742
6. 金倉 謙監修. 血液診療エキスパート 貧血. 東京 : 中外医学社, 2010 : 6-7.
7. Corwin HL, et al. Erythropoietin response in critically ill patients. Crit Care Med 1997 ; 25 (suppl 1) : 82.
8. Vincent JL, et al. Anemia and blood transfusion in critically ill patients. JAMA 2002 ; 288 : 1499-507. PMID : 12243637
9. Prakash D. Anemia in the ICU : anemia of chronic disease versus anemia of acute illness. Crit Care Clin 2012 ; 28 : 333-43, v. PMID : 22713609
10. Smoller BR, et al. Phlebotomy for diagnostic laboratory tests in adults. Pattern of use and effect on transfusion requirements. N Engl J Med 1986 ; 314 : 1233-5. PMID : 3702919
11. Nemeth E, et al. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science 2004 ; 306 : 2090-3. PMID : 15514116
12. Bobbio-Pallavicini F, et al. Body iron status in critically ill patients : significance of serum ferritin. In-

- tensive Care Med 1989 ; 15 : 171-8. PMID : 2738221
13. Heming N, et al. Iron deficiency in critically ill patients : highlighting the role of hepcidin. Crit Care Med 2011 ; 15 : 210. PMID : 21457511
14. Jones JG, et al. Total circulating red cells versus haematocrit as the primary descriptor of oxygen transport by the blood. Br J Haematol 1990 ; 76 : 288-94. PMID : 2094332
15. Cordts PR, et al. Poor predictive value of hematocrit and hemodynamic parameters for erythrocyte deficits after extensive elective vascular operations. Surg Gynecol Obstet 1992 ; 175 : 243-8. PMID : 1514159
16. Sadaka F, et al. Transfusion of red blood cells is associated with improved central venous oxygen saturation but not mortality in septic shock patients. J Clin Med Res 2014 ; 6 : 422-8. PMID : 25247015
17. Corwin HL, et al. RBC transfusion in the ICU. Is there a reason? Chest 1995 ; 108 : 767-71. PMID : 7656631
18. Hébert PC, et al. A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. Transfusion Requirements in Critical Care Investigators, Canadian Critical Care Trials Group. N Engl J Med 1999 ; 340 : 409-17. PMID : 9971864
19. Hébert PC, et al. Is a low transfusion threshold safe in critically ill patients with cardiovascular diseases? Crit Care Med 2001 ; 29 : 227-34. PMID : 11246298
20. Corwin HL, et al. The CRIT Study : Anemia and blood transfusion in the critically ill — current clinical practice in the United States. Crit Care Med 2004 ; 32 : 39-52. PMID : 14707558
21. Vamvakas EC, et al. Deleterious clinical effects of transfusion-associated immunomodulation : fact or fiction? Blood 2001 ; 97 : 1180-95. PMID : 11222359
22. Chapter 5. In : Hillman RS, et al. Hematology in clinical practice. 5th ed. Lange, 2010, 6673-7210.
23. Corwin HL, et al. Efficacy and safety of epoetin alfa in critically ill patients. N Engl J Med 2007 ; 357 : 965-76. PMID : 17804841
24. Zarychanski R, et al. Erythropoietin-receptor agonists in critically ill patients : a meta-analysis of randomized controlled trials. CMAJ 2007 ; 177 : 725-34. PMID : 17823140
25. Hoen B, et al. Intravenous iron administration does not significantly increase the risk of bacteremia in chronic hemodialysis patients. Clin Nephrol 2002 ; 57 : 457-61. PMID : 12078950
26. Pieracci FM, et al. Randomized, double-blind, placebo-controlled trial of effects of enteral iron supplementation on anemia and risk of infection during surgical critical illness. Surg Infect (Larchmt) 2009 ; 10 : 9-19. PMID : 19245362

第4章 凝固異常

● 参考文献

1. Peyvandi F, et al. Rare bleeding disorders. Haemophilia 2006 ; 12 Suppl 3 : 137-42. PMID : 16684009
2. Acharya SS, et al. Rare Bleeding Disorder Registry : deficiencies of factors II, V, VII, X, XIII, fibrinogen and dysfibrinogenemias. J Thromb Haemost 2004 ; 2 : 248-56. PMID : 14995986
3. Wheeler AP, et al. Coagulopathy in critically ill patients : part 2—soluble clotting factors and hemostatic testing. Chest 2010 ; 137 : 185-94. PMID : 20051403
4. Kaneko T, et al. Diagnostic criteria and laboratory tests for disseminated intravascular coagulation. J Clin Exp Hematop 2011 ; 51 : 67-76. PMID : 22104305
5. Hunt BJ. Bleeding and coagulopathies in critical care. N Engl J Med 2014 ; 370 : 847-59. PMID : 24571757
6. Borgman MA, et al. The ratio of blood products transfused affects mortality in patients receiving massive transfusions at a combat support hospital. J Trauma 2007 ; 63 : 805-13. PMID : 18090009
7. Holcomb JB, et al. The prospective, observational, multicenter, major trauma transfusion (PROMTTT)

- study : comparative effectiveness of a time-varying treatment with competing risks. *JAMA Surg* 2013 ; 148 : 127-36. PMID : 23560283
8. Holbrook A, et al. Evidence-based management of anticoagulant therapy : Antithrombotic Therapy and Prevention of Thrombosis, 9th ed : American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. *Chest* 2012 ; 141 (2 Suppl) : e152S-84S. PMID : 22315259
 9. Fredriksson K, et al. Emergency reversal of anticoagulation after intracerebral hemorrhage. *Stroke* 1992 ; 23 : 972-7. PMID : 1615547
 10. Cartmill M, et al. Prothrombin complex concentrate for oral anticoagulant reversal in neurosurgical emergencies. *Br J Neurosurg* 2000 ; 14 : 458-61. PMID : 11198768
 11. Boulis NM, et al. Use of factor IX complex in warfarin-related intracranial hemorrhage. *Neurosurgery* 1999 ; 45 : 1113-8 ; discussion 1118-9. PMID : 10549927
 12. Burbury KL, et al. Short-term warfarin reversal for elective surgery—using low-dose intravenous vitamin K : safe, reliable and convenient. *Br J Haematol* 2011 ; 154 : 626-34. PMID : 21751986
 13. Dezee KJ, et al. Treatment of excessive anticoagulation with phytonadione (vitamin K) : a meta-analysis. *Arch Intern Med* 2006 ; 166 : 391-7. PMID : 16505257
 14. Siegal DM, et al. How I treat target-specific oral anticoagulant-associated bleeding. *Blood* 2014 ; 123 : 1152-8. PMID : 24385535
 15. Siegal DM, et al. Acute management of bleeding in patients on novel oral anticoagulants. *Eur Heart J* 2013 ; 34 : 489-498b. PMID : 23220847
 16. Kearon C, et al. Antithrombotic Therapy for VTE Disease : CHEST Guideline and Expert Panel Report. *Chest* 2016 ; 149 : 315-52. PMID : 26867832
 17. Jain A, et al. Antithrombotic Therapy for Venous Thromboembolic Disease. *JAMA* 2017 ; 317 : 2008-9. PMID : 28510665
 18. Wada H, et al. Guidance for diagnosis and treatment of DIC from harmonization of the recommendations from three guidelines. *J Thromb Haemost* 2013 Feb 4. [Epub ahead of print] PMID : 23379279
 19. Levi M, et al. Prophylactic heparin in patients with severe sepsis treated with drotrecogin alfa (activated). *Am J Respir Crit Care Med* 2007 ; 176 : 483-90. PMID : 17556722
 20. Levi M, et al. Guidelines for the diagnosis and management of disseminated intravascular coagulation. British Committee for Standards in Haematology. *Br J Haematol* 2009 ; 145 : 24-33. PMID : 19222477
 21. 日本血栓止血学会学術標準化委員会 DIC 部会. 科学的根拠に基づいた感染症に伴う DIC 治療のエキスポートコンセンサス (2009 年 2 月). *日血栓止血会誌* 2009 ; 20 : 77-113.<http://kohmura-dm.sakura.ne.jp/m_kessen/wp-content/uploads/2015/04/DIC.pdf>
 22. Blauhut B, et al. Substitution of antithrombin III in shock and DIC : a randomized study. *Thromb Res* 1985 ; 39 : 81-9. PMID : 4035650
 23. Kienast J, et al. Treatment effects of high-dose antithrombin without concomitant heparin in patients with severe sepsis with or without disseminated intravascular coagulation. *J Thromb Haemost* 2006 ; 4 : 90-7. PMID : 16409457
 24. Saito H, et al. Efficacy and safety of recombinant human soluble thrombomodulin (ART-123) in disseminated intravascular coagulation : results of a phase III , randomized, double-blind clinical trial. *J Thromb Haemost* 2007 ; 5 : 31-41. PMID : 17059423
 25. Yamakawa K, et al. Treatment effects of recombinant human soluble thrombomodulin in patients with severe sepsis : a historical control study. *Crit Care* 2011 ; 15 : R123. PMID : 21569368